benmelstobart + etoposide

benmelstobart + etoposide is a combination regimen consisting of benmelstobart, a humanized IgG1 monoclonal antibody targeting programmed cell death-1 ligand-1 (PD-L1), and etoposide, a semisynthetic podophyllotoxin derivative that acts as a topoisomerase II inhibitor. Benmelstobart functions as an immune checkpoint inhibitor by blocking the interaction between PD-L1 and its receptor PD-1, thereby restoring T-cell-mediated anti-tumor immune responses. Etoposide stabilizes the transient topoisomerase II-DNA cleavage complex, preventing DNA re-ligation and leading to the accumulation of double-strand DNA breaks, which triggers cell cycle arrest and apoptosis in rapidly dividing cancer cells. This combination is primarily developed and evaluated in combination with other agents (such as anlotinib and carboplatin) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) and limited-stage small cell lung cancer (LS-SCLC).

Other names

APL-502 + etoposideCBT-502 + etoposideTQB2450 + etoposideTQB2450 and etoposideTQB-2450 and etoposideTQB 2450 and etoposidebenmelstobart and etoposideetoposide + benmelstobartetoposide and benmelstobart